| Course | NU648 Specialized Pharmacology for the AGACNP |
|---|---|
| Unit | Unit 10 |
| Paper type | Agent comparison paper |
| Length | About 1,100 words, 6 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU648 Unit 10
Fidaxomicin Over Oral Vancomycin for a First Clostridioides difficile Infection in a 79-Year-Old Who Still Needs Systemic Antibiotics: An Agent Comparison
[Student Name]
Purdue University Global
NU648: Specialized Pharmacology for the AGACNP
Unit 10 Agent Comparison Paper
[Instructor Name]
[Date]
The patient is composite; laboratory values, doses and coverage details are bracketed.
The Question and the Answer
Mrs. [L.] is a [79]-year-old woman with a first episode of Clostridioides difficile infection. She must continue intravenous cefazolin for [four] more weeks to treat a methicillin-susceptible Staphylococcus aureus infection of her right knee replacement. The question is which agent to use for her C. difficile infection: fidaxomicin [200 mg] twice daily for [ten] days or oral vancomycin [125 mg] four times daily for [ten] days. This paper recommends fidaxomicin. The two agents tie on initial cure, but fidaxomicin reduces recurrence, and her ongoing antibiotic and her age put her at exactly the risk that difference addresses.
Background
Her diarrhea began [nine] days after a [seven]-day course of amoxicillin-clavulanate for sinusitis, prescribed at an urgent care visit. She has taken omeprazole [20 mg] daily for [six] years for reflux that has been quiet for most of that time. She now has [five] to [seven] loose stools a day, mild cramping and no fever. Her white blood cell count is [11,200] per microliter and her creatinine [0.9] mg/dL, which makes this a nonsevere episode by the usual criteria. Her stool was positive for toxin. Both the amoxicillin-clavulanate and the long-term proton pump inhibitor are recognized contributors, and the plan addresses both.
The knee infection is the complication. Treatment guidelines prefer stopping the antibiotics that provoked C. difficile when possible, but her cefazolin cannot be stopped without risking the prosthesis.
Evidence, Organized by Outcome
Initial clinical cure
Two phase 3 trials randomized adults with C. difficile infection to fidaxomicin or vancomycin for ten days. In the North American trial of 629 patients, clinical cure was 88.2 percent with fidaxomicin and 85.8 percent with vancomycin in the modified intention-to-treat analysis, meeting the prespecified test for noninferiority (Louie et al., 2011). The European, Canadian and United States trial of 535 patients found the same pattern, 87.7 percent against 86.8 percent (Cornely et al., 2012). On the first outcome, the agents tie.
Recurrence
The difference appears after treatment ends. In the North American trial, recurrence within four weeks was 15.4 percent with fidaxomicin and 25.3 percent with vancomycin (Louie et al., 2011). The advantage was seen in infections with strains other than the North American pulsed-field type 1 strain, a detail the trial reported and that a careful reader should not drop. An extended-pulsed fidaxomicin regimen was tested in hospitalized adults aged 60 and older in EXTEND. Sustained cure 30 days after the end of treatment was 70 percent with extended-pulsed fidaxomicin and 59 percent with standard vancomycin (Guery et al., 2018).
On cure the two drugs are equal; on keeping the infection from coming back, fidaxomicin is better, and recurrence is the outcome that follows older patients home.
Patients who must continue other antibiotics
Her situation has its own evidence. Pooling both phase 3 trials, investigators studied patients who received other antibiotics while being treated for C. difficile. In that group, cure was 90.0 percent with fidaxomicin and 79.4 percent with vancomycin, and recurrence was lower with fidaxomicin among patients who received other antibiotics during treatment or follow-up (Mullane et al., 2011). Cornely et al. (2012) found a similar cure difference in their own subgroup taking concomitant antibiotics. These are subgroup analyses and should be read with that caution, but they point the same way as the main results.
Safety and cost
Adverse events did not differ meaningfully between the drugs in either phase 3 trial. Cost does differ. A ten-day course of fidaxomicin costs several times more than oral vancomycin at most pharmacies, and coverage under Medicare Part D varies by plan. Cost is a real outcome for Mrs. [L.], because a drug she cannot obtain treats nothing.
What the Guideline Says
The 2021 IDSA and SHEA focused update suggests fidaxomicin rather than a standard course of vancomycin for an initial episode, as a conditional recommendation with moderate certainty of evidence, and keeps vancomycin as an acceptable alternative (Johnson et al., 2021). The strength of that recommendation matters. It is conditional, which means the panel expected reasonable clinicians to choose differently for some patients, particularly where cost or access stands in the way. The guideline follows the trial evidence here rather than leading it, and the paper reports it in that order.
Applying the Evidence to Mrs. [L.]
Three features of her case raise her risk of recurrence: age over 65, continued exposure to a systemic antibiotic and a proton pump inhibitor. Recurrence is the outcome on which fidaxomicin has an advantage, and her ongoing cefazolin places her in the subgroup where cure also favored fidaxomicin. A recurrence during her knee treatment could interrupt physical therapy, delay her return home and expose her to further courses of therapy.
The plan is fidaxomicin [200 mg] twice daily for [ten] days, with three supporting steps:
1. Coverage: the pharmacy submits a prior authorization on the day of diagnosis, and the case manager checks the manufacturer's patient assistance program in parallel.
2. Contributors: omeprazole is reviewed with her primary care provider, since her reflux has been quiet, with a plan to taper and stop if no ongoing indication is found.
3. Contingency: if fidaxomicin cannot be obtained within [24] hours, oral vancomycin [125 mg] four times daily starts at once, because delay is worse than the second-choice agent.
She will be taught to report any return of diarrhea after the course ends, and her infectious diseases team will be told about the C. difficile infection so that her cefazolin course is not extended beyond what the knee requires.
Limitations
The trials have limits that bear on this recommendation. Both phase 3 trials excluded patients with life-threatening disease and some with multiple prior episodes, and many frail older adults do not enter drug trials at all. The recurrence advantage in the North American trial depended on the strain, and hospitals rarely know the strain when they choose a drug. EXTEND was open label, was run in European hospitals and tested a different fidaxomicin schedule from the one most United States pharmacies dispense. The concomitant antibiotic data come from subgroups. None of these limits reverses the recommendation, but together they explain why the guideline is conditional, and why the contingency plan in this paper is part of the recommendation rather than an afterthought.
References
Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012). Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. The Lancet Infectious Diseases, 12(4), 281-289. https://doi.org/10.1016/S1473-3099(11)70374-7
Guery, B., Menichetti, F., Anttila, V.-J., Adomakoh, N., Aguado, J. M., Bisnauthsing, K., Georgopali, A., Goldenberg, S. D., Karas, A., Kazeem, G., Longshaw, C., Palacios-Fabrega, J. A., Cornely, O. A., & Vehreschild, M. J. G. T. (2018). Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): A randomised, controlled, open-label, phase 3b/4 trial. The Lancet Infectious Diseases, 18(3), 296-307. https://doi.org/10.1016/S1473-3099(17)30751-X
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021). Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases, 73(5), e1029-e1044. https://doi.org/10.1093/cid/ciab549
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine, 364(5), 422-431. https://doi.org/10.1056/NEJMoa0910812
Mullane, K. M., Miller, M. A., Weiss, K., Lentnek, A., Golan, Y., Sears, P. S., Shue, Y.-K., Louie, T. J., & Gorbach, S. L. (2011). Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clinical Infectious Diseases, 53(5), 440-447. https://doi.org/10.1093/cid/cir404
Reading the NU 648 Unit 10 instructions
The Unit 10 assignment asks you to compare two drugs for one clinical problem and recommend one for a specific patient. You state the question, give the clinical background, compare the agents on efficacy, safety and cost using primary trials, report what current guidelines say, apply the evidence to the patient and discuss the limits of the evidence. Most sections set five to six pages. The paper should commit to an answer early and defend it; a comparison that ends by calling both drugs acceptable usually earns fewer points than one that chooses and explains when it would choose otherwise. Primary trials should carry the evidence section, with the guideline reported after them rather than in their place.
How the NU 648 Unit 10 example is put together
The example states its answer in the first section and spends the rest earning it. The background names two contributors to her infection, a recent antibiotic course and a long-term proton pump inhibitor, and the one antibiotic that cannot stop. The evidence is sorted by outcome rather than by study, so the reader sees the tie on cure and the gap on recurrence. The concomitant antibiotic subgroups get their own section with a caution about subgroups. The guideline is reported after the trials, with its strength. The patient section gives three supporting steps, including a contingency if coverage fails. A closing section on limitations names what each trial could not show and explains why those gaps make the guideline conditional.
Where the points sit in the NU648 Unit 10 rubric
The Unit 10 rubric looks at the clarity of the recommendation, the quality and accuracy of the evidence, the application to the patient, the discussion of limitations and APA format. Clarity earns full points when the answer is stated early. Evidence is judged on reporting numbers correctly with their populations, such as 15.4 against 25.3 percent recurrence. Application counts when the patient's features are tied to the outcome where the drugs differ. Limitations earn credit when they are specific to each trial, not generic. Format and mechanics carry fewer points but are easy to lose with missing DOIs or out-of-order references. Every figure should match its source exactly.
NU648 Unit 10 help from the desk
The most common mistake is surveying both drugs without choosing, or choosing in the last paragraph. Another is reporting the recurrence advantage without its limits, including the strain detail in the North American trial. Students often cite the guideline as the main evidence rather than the trials behind it, or misstate a conditional recommendation as a strong one. Cost is sometimes waved away, though it decides what a patient can take home. Many papers forget contributors such as a proton pump inhibitor. And a recommendation without a backup plan leaves the patient untreated when the first choice is not available.
Get an NU648 Unit 10 example written to your instructions
Name the pair of drugs your NU648 Unit 10 prompt pits against one another, and share the case, required sources and rubric. Free the first time and generally ready within 24-48h, the sample states its choice early, reads the trials by outcome, and lets the patient's own risks settle the comparison. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU648 papers and MSN samples
- NU648 Unit 1: Hypoglycemia Medication Review Post
- NU648 Unit 2: Dosing Weight Worksheet
- NU648 Unit 3: Adverse Drug Event Analysis
- NU648 Unit 4: Perioperative Medication Plan
- NU648 Unit 5: Seminar Reflection on Xa Reversal
- NU648 Unit 6: Multimodal Pain Plan on Buprenorphine
- NU648 Unit 7: QT Prolongation Risk Review
- NU648 Unit 8: Beers Criteria Prescribing Review
- NU648 Unit 9: Electrolyte Replacement Case
- NU610 Unit 10: Oral Case Presentation Outline
- NU605 Unit 10: First-year Practice Plan
- NU603 Unit 10: Sustainability Plan
- NU590 Unit 10: Practicum Summary Paper
NU648 Unit 10 questions, answered
Must the paper commit to one agent?
Most prompts for this assignment ask for a defended choice, and a paper concluding that both are fine usually loses credit for avoiding the question. The sample commits to one and states the conditions under which the other would be preferred, which shows the choice was reasoned rather than arbitrary.
Can cost be part of the argument?
Yes, and in hospital medicine it often decides what a patient can actually take home. The sample treats cost as a real factor, describes checking coverage, and keeps an alternative in reserve should the preferred agent be out of reach, without letting price replace the clinical comparison. Specific prices are left out, since they vary.
Where can I find a free NU648 Unit 10 sample paper?
The full NU648 Unit 10 agent comparison paper is on this page, with the question, the trial evidence by outcome, the 2021 guideline, the patient application and the limitations. A free sample comparing the agents in your own prompt can be requested.
Is fidaxomicin preferred over vancomycin in NU648 Unit 10?
For an initial episode, the 2021 IDSA and SHEA update suggests fidaxomicin over a standard vancomycin course as a conditional recommendation, and keeps vancomycin as an acceptable alternative. The sample follows that and explains why this patient's risk of recurrence favors fidaxomicin.
Which trials should an NU648 Unit 10 comparison cite?
The two phase 3 trials comparing the drugs, by Louie and by Cornely, the EXTEND trial in adults aged 60 and older and, for patients on other antibiotics, the pooled subgroup analysis by Mullane. The sample also cites the 2021 guideline update.